Roland Walter

All articles published by MDPI are made immediately available worldwide under an open access license. No special permission is required to reuse all or part of the article published by MDPI, including figures and tables. For articles published under an open access Creative Common CC BY license, any part of the article may be reused without permission provided that the original article is clearly cited. For more information, please refer to https://www.mdpi.com/openaccess.

Get full text access Log in, subscribe or purchase for full access. References 1. Papaemmanuil, E ∙ Döhner, H ∙ Campbell, PJ Genomic classification in acute myeloid leukemia N Engl J Med. 2016; 375:900-901 2. Döhner, H ∙ Estey, E ∙ Grimwade, D ∙ et al. Diagnosis and management of AML in adults: 2017 ELN recommendations from an international expert panel Blood. 2017; 129:424-447 3. Falini, B ∙ Mecucci, C ∙ Tiacci, E ∙ et al.

Informed treatment decision-making in acute myeloid leukemia (AML) requires a comprehensive evaluation of all clinical and biological features that may affect the outcome with any given type or intensity of therapy. This process needs to encompass an assessment of both the clinical fitness of the patient and the biological characteristics of the disease.